LAV

IMPACT Announces Completion of RMB 250 million Sr. D++ Financing

2024年11月15日

SHANGHAI, November 15th, 2024 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company...

GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline

2024年10月29日

CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B...

Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer

2024年9月30日

Cambridge, Massachusetts, September 30, 2024 - Regor Pharmaceuticals (USA) ("Regor") has entered...

ImmuneOnco and Instil Bio Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

2024年8月2日

Shanghai, China and Dallas, TX, August 01, 2024 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ...

Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms

2024年7月19日

- Financing led by LongRiver Investments with participation by new and existing global...

AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease

2024年6月13日

- Global license agreement to focus on the development of FG-M701, a TL1A antibody, for the...

Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment

2024年5月16日

Acquisition advances Johnson & Johnson’s leading Dermatology portfolio with opportunity to...

The Phase 3 clinical trial data of Senaparib published in Nature Medicine, positioning it as a promising first-line maintenance treatment option for the all-comer population in advanced ovarian cancer

2024年5月15日

On May 15, 2024, the internationally renowned medical journal Nature Medicine (Latest impact...

Impact Raises RMB 400 million in Series D+ Funding

2024年4月19日

SHANGHAI, April 19th, 2024 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company...

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

2024年4月4日

Genmab to acquire ProfoundBio for USD 1.8 billion in cashAcquisition will give Genmab...

NDA of AGAMREE was Accepted and Granted Priority Review by China’s CDE

2024年3月26日

March 26, 2024, the NDA filling of AGAMREE (vamorolone) is indicated for the treatment of...

Scivita Medical Expands Collaboration with Boston Scientific

2024年3月26日

Recently, Scivita Medical Technology Co., Ltd. (“Scivita Medical”) and Boston Scientific...

NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma

2024年3月1日

SHANGHAI, China, March 1, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a...

ProfoundBio Raises $112 Million in Oversubscribed Series B Equity Financing to Advance its Clinical-Stage Antibody-Drug Conjugate (ADC) Pipeline

2024年2月14日

– Proceeds to support development of ProfoundBio's differentiated clinical-stage ADC pipeline...

ArriVent Announces Pricing of Upsized Initial Public Offering

2024年1月25日

NEWTOWN SQUARE, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) ...

Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases

2023年12月27日

Proposed acquisition will enrich the AstraZeneca cell therapy pipeline with clinical-stage...

IMPACT Therapeutics Presented Pivotal Phase 3 Clinical Data for Senaparib as First-line Maintenance Therapy in Advanced Ovarian Cancer Patients at ESMO Congress 2023 as a Proffered Late-Breaking Paper Presentation

2023年10月20日

On October 20, 2023, IMPACT Therapeutics presented, in the form of proffered paper presentation,...

Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors

2023年6月2日

SHANGHAI, China and HAYWARD, Calif., June 1, 2023 – IMPACT Therapeutics (“Impact”), a...

Rona Therapeutics and Keymed Biosciences Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for Glomerulonephritis

2023年5月15日

SHANGHAI, May 15, 2023 /PRNewswire/ -- Rona Therapeutics, Inc ("Rona") and Keymed Biosciences...

Alebund Pharmaceuticals Closes Nearly RMB 200 Million Pre-C Round Financing and Secures RMB 800 Million Syndicated Loan Credit

2023年4月12日

Shanghai, China, April 12th, 2023—Alebund Pharmaceuticals (“Alebund” or the “Company”)...

All Categories - LAV